Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)

References

• Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–1421.
   PubMed Web of Science ®Google Scholar
• Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci. 2000;25(10):496–502.
   PubMed Web of Science ®Google Scholar
• Steen HC, Gamero AM. STAT2 phosphorylation and signaling. Jakstat. 2013;2(4):e25790.
   PubMedGoogle Scholar
• Wurster AL, Tanaka T, Grusby MJ. The biology of Stat4 and Stat6. Oncogene. 2000;19(21):2577–2584.
   PubMed Web of Science ®Google Scholar
• Zhuang SG. Regulation of STAT signaling by acetylation. Cell Signal. 2013;25(9):1924–1931.
   PubMed Web of Science ®Google Scholar
• Wingelhofer B, Neubauer HA, Valent P, et al. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. 2018;32(8):1713–1726.
   PubMed Web of Science ®Google Scholar
• Dong J, Cheng XD, Zhang WD, et al. Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation. J Med Chem. 2021;64(13):8884–8915.
   PubMed Web of Science ®Google Scholar
• Hevehan DL, Miller WM, Papoutsakis ET. Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation. Blood. 2002;99(5):1627–1637.
   PubMed Web of Science ®Google Scholar
• Benekli M, Baer MR, Baumann H, et al. Signal transducer and activator of transcription proteins in leukemias. Blood. 2003;101(8):2940–2954.
   PubMed Web of Science ®Google Scholar
• Sgrignani J, Garofalo M, Matkovic M, et al. Structural biology of stat3 and its implications for anticancer therapies development. Int J Mol Sci. 2018;19(6):1591.
   PubMed Web of Science ®Google Scholar
• Ma J, Zhang T, Novotny-Diermayr V, et al. A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation. J Biol Chem. 2003;278(31):29252–29260.
   PubMed Web of Science ®Google Scholar
• Horvath CM, Wen Z, Darnell JE Jr. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 1995;9(8):984–994.
   PubMed Web of Science ®Google Scholar
• Mertens C, Haripal B, Klinge S, et al. Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity. Proc Natl Acad Sci U S A. 2015;112(48):14811–14816.
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene. 2000;19(21):2474–2488.
   PubMed Web of Science ®Google Scholar
• Hu T, Yeh JE, Pinello L, et al. Impact of the N-terminal Domain of STAT3 in STAT3-dependent transcriptional activity. Mol Cell Biol. 2015;35(19):3284–3300.
   PubMed Web of Science ®Google Scholar
• Avalle L, Camporeale A, Camperi A, et al. STAT3 in cancer: a double edged sword. Cytokine. 2017;98:42–50.
   PubMed Web of Science ®Google Scholar
• Balic JJ, Albargy H, Luu K, et al. STAT3 serine phosphorylation is required for TLR4 metabolic reprogramming and IL-1β expression. Nat Commun. 2020;11(1):3816.
   PubMed Web of Science ®Google Scholar
• Hazan-Halevy I, Harris D, Liu Z, et al. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood. 2010;115(14):2852–2863.
   PubMed Web of Science ®Google Scholar
• Fletcher S, Page BD, Zhang X, et al. Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. Chem Med Chem. 2011;6(8):1459–1470.
   Google Scholar
• Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–746.
   PubMed Web of Science ®Google Scholar
• Qin JH, Shen XF, Zhang J, et al. Allosteric inhibitors of the STAT3 signaling pathway. Eur J Med Chem. 2020;190:112122.
   PubMed Web of Science ®Google Scholar
• Furtek SL, Matheson CJ, Backos DS, et al. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors. Oncotarget. 2016;7(47):77998–78008.
   PubMedGoogle Scholar
• Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–248.
   PubMed Web of Science ®Google Scholar
• Yuan ZL, Guan YJ, Chatterjee D, et al. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005;307(5707):269–273.
   PubMed Web of Science ®Google Scholar
• Lee H, Zhang P, Herrmann A, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A. 2012;109(20):7765–7769.
   PubMed Web of Science ®Google Scholar
• Yang R, Rincon M. Mitochondrial Stat3, the Need for Design Thinking. Int J Biol Sci. 2016;12(5):532–544.
   PubMed Web of Science ®Google Scholar
• Sonnenblick A, Shriki A, Galun E, et al. Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clin Transl Oncol. 2012;14(3):232–236.
   PubMed Web of Science ®Google Scholar
• Lin L, Liu AG, Peng ZG, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 2011;71(23):7226–7237.
   PubMed Web of Science ®Google Scholar
• You W, Tang QY, Zhang CY, et al. IL-26 promotes the proliferation and survival of human gastric cancer cells by regulating the balance of STAT1 and STAT3 activation. PLoS One. 2013;8(5):e63588.
   PubMed Web of Science ®Google Scholar
• Pancotti F, Roncuzzi L, Maggiolini M, et al. Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. Cell Signal. 2012;24(7):1390–1397.
   PubMed Web of Science ®Google Scholar
• Geiger JL, Grandis JR, Bauman JE. The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations. Oral Oncol. 2016;56:84–92.
   PubMed Web of Science ®Google Scholar
• Saini U, Naidu S, ElNaggar AC, et al. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene. 2017;36(2):168–181.
   PubMed Web of Science ®Google Scholar
• Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin’s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res. 2003;9(1):316–326.
   PubMed Web of Science ®Google Scholar
• Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta. 2014;1845(2):136–154.
   PubMed Web of Science ®Google Scholar
• Wang T, Fahrmann JF, Lee H, et al. JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab. 2018;27(1):136–50.e5.
   PubMed Web of Science ®Google Scholar
• Furtek SL, Backos DS, Matheson CJ, et al. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem Biol. 2016;11(2):308–318.
   PubMed Web of Science ®Google Scholar
• Rosenzweig SA. Acquired resistance to drugs targeting tyrosine kinases. Adv Cancer Res. 2018;138:71–98.
   PubMed Web of Science ®Google Scholar
• Wu P, Nielsen TE, Clausen MH. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov Today. 2016;21(1):5–10.
   PubMed Web of Science ®Google Scholar
• Huang QY, Zhong Y, Dong H, et al. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: where are we and where should we go? Eur J Med Chem. 2020;187:111922.
   PubMed Web of Science ®Google Scholar
• Lin L, Hutzen B, Li PK, et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia. 2010;12(1):39–50.
   PubMed Web of Science ®Google Scholar
• Lavecchia A, Di Giovanni C, Cerchia C. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature. Expert Opin Ther Pat. 2014;24(4):383–400.
   PubMed Web of Science ®Google Scholar
• Yu WY, Xiao H, Lin JY, et al. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J Med Chem. 2013;56(11):4402–4412.
   PubMed Web of Science ®Google Scholar
• Li CL, Yu WY, Jiayuh L, et al. STAT3 inhibitors and their anticancer use. WO2014028909. 2014.
   Google Scholar
• Yu WY, Li CL, Zhang WD, et al. Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking. J Med Chem. 2017;60(7):2718–2731.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang H, Guan LN, et al. LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo. Br J Pharmacol. 2020;177(2):298–313.
   PubMed Web of Science ®Google Scholar
• Yu WY, Lai C, Yu KQ. Compound LL-1 preparation method. CN106946810. 2017.
   Google Scholar
• Yang YH, Li CL, Racke M. Methods and compositions for inhibition of STAT3. WO201906769. 2019.
   Google Scholar
• Zhang RJ, Yang XZ, Roque DM, et al. A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin. PLoS One. 2021;16(4):e0240145.
   PubMed Web of Science ®Google Scholar
• Yu WY, Liu Z. A class of compound and its preparation method and use. CN112979578. 2021.
   Google Scholar
• Yu WY, Zhang J, Li ZL, et al. A class of compounds and their medical use for colorectal cancer. CN112939824. 2021.
   Google Scholar
• Yu WY, Lai MD. 1. A class of compounds and their medical use for COVID-19. CN112920136. 2021.
   Google Scholar
• Hubbard JM, Grothey A. Napabucasin: an update on the first-in-class cancer stemness inhibitor. Drugs. 2017;77(10):1091–1103.
   PubMed Web of Science ®Google Scholar
• Chen GL, Zhou QP, Du FY, et al. BBI608 derivative as well as preparation and application thereof. CN107973788. 2018.
   Google Scholar
• Zhou QF, Peng C, Du FY, et al. Design, synthesis and activity of BBI608 derivatives targeting on stem cells. Eur J Med Chem. 2018;151:39–50.
   PubMed Web of Science ®Google Scholar
• Cai X, Zhong XB. Furoquinoline diketone compounds and medicinal application thereof. CN107501279. 2017.
   Google Scholar
• Li RT, Li RR, Ge ZM, et al. Furan-naphthoquinone-based sulfoximine derivative and use of same in preparation of STAT3 inhibitor. WO201900741. 2019.
   Google Scholar
• Li RT, Li RR, Ge ZM, et al. Furan-naphthoquinone-based sulfoximine derivative and use of same in preparation of STAT3 inhibitor. CN109206390. 2019.
   Google Scholar
• Xie P, Chen XG, Jiao XZ. 2, 3-dihydronaphthalo [2, 3-b] furan-4, 9-diketone compound as well as preparation method and application thereof. CN111825644. 2019.
   Google Scholar
• Texas A&M University System. STAT3 inhibitor. WO2014113467. 2014.
   Google Scholar
• Chen HJ, Yang ZD, Ding CY, et al. Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur J Med Chem. 2013;62:498–507.
   PubMed Web of Science ®Google Scholar
• Chen HJ, Yang ZD, Ding CY, et al. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). Eur J Med Chem. 2014;82:195–203.
   PubMed Web of Science ®Google Scholar
• Qiao CH, Ji P. Targeting STAT3 inhibitor and application thereof. CN104844563. 2015.
   Google Scholar
• Ji P, Xu X, Ma SH, et al. Novel 2-carbonylbenzo[b]thiophene 1,1-dioxide derivatives as potent inhibitors of STAT3 signaling pathway. ACS Med Chem Lett. 2015;6(9):1010–1014.
   PubMed Web of Science ®Google Scholar
• Wang YX, Zhang XL, Huang QY, et al. Quinoline STAT3 specific inhibitor, and preparation method and applications thereof. CN110105279. 2019.
   Google Scholar
• Huang QY, Zhong Y, Li BB, et al. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). Eur J Med Chem. 2021;221:113525.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Wang YX, Liu PQ, et al. Micromolecule STAT3 inhibitor WZ-2-033 and application thereof to preparation of medicines for treating breast cancer and stomach cancer. CN111658644. 2020.
   Google Scholar
• Zhong Y, Deng L, Shi S, et al. The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts [published online ahead of print, 2021 Jul 15]. Acta Pharmacol Sin. 2021. DOI:https://doi.org/10.1038/s41401-021-00718-0.
   Google Scholar
• Chen HJ, Yang ZD, Ding CY, et al. Discovery of O-alkylamino tethered niclosamide derivatives as potent and orally bioavailable anticancer agents. ACS Med Chem Lett. 2013;4(2):180–185.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang SN, Wu YS, et al. Suppression of the growth and invasion of human head and neck squamous cell carcinomas via regulating STAT3 signaling and the miR-21/β-catenin axis with HJC0152. Mol Cancer Ther. 2017;16(4):578–590.
   PubMed Web of Science ®Google Scholar
• Jiang XX, Wu MJ, Xu ZZ, et al. HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer. Cancer Manag Res. 2018;10:6857–6867.
   PubMed Web of Science ®Google Scholar
• Li ZQ, Zhu TT, Xu YN, et al. A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma. Am J Cancer Res. 2019;9(4):699–713.
   PubMed Web of Science ®Google Scholar
• Lu L, Li H, Wu X, et al. HJC0152 suppresses human non-small-cell lung cancer by inhibiting STAT3 and modulating metabolism. Cell Prolif. 2020;53(3):e12777.
   PubMed Web of Science ®Google Scholar
• Ye FQ, Han C, Cheng DH, et al. 4-chlorine-N-substituted phenyl-3-sulfonyl aminobenzamide compound and preparation and anti-tumor application of 4-chlorine-N-substituted phenyl-3-sulfonyl aminobenzamide compound. CN108997176. 2018.
   Google Scholar
• Wang XB, Wu KQ, Fang LC, et al. Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide. Eur J Med Chem. 2021;218:113362.
   PubMed Web of Science ®Google Scholar
• Reigan P, Backos DS, Matheson CJ, et al. STAT3 transcription factor inhibitors and methods of using the same. WO2020118265. 2020.
   Google Scholar
• Xu H, Chen XG, Lin SW, et al. Benzamide compound and preparation method, use, and pharmaceutical composition thereof. WO2019149223. 2019.
   Google Scholar
• Xu H, Chen XG, Lin SW, et al. Benzamide-based compound, preparation method and uses thereof, and pharmaceutical composition. CN110092743. 2019.
   Google Scholar
• Chen Y, Ji M, Zhang S, et al. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer. J Drug Target. 2018;26(10):920–930.
   PubMed Web of Science ®Google Scholar
• University of Hawaii. 2-Arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors. WO2018136935. 2018.
   Google Scholar
• Lai PS, Rosa DA, Magdy Ali A, et al. A STAT inhibitor patent review: progress since 2011. Expert Opin Ther Pat. 2015;25(12):1397–1421.
   PubMed Web of Science ®Google Scholar
• Lopez-Tapia F, Brotherton-Pleiss C, Yue P, et al. Linker variation and structure-activity relationship analyses of carboxylic acid-based small molecule STAT3 inhibitors. ACS Med Chem Lett. 2018;9(3):250–255.
   PubMed Web of Science ®Google Scholar
• Brotherton-Pleiss C, Yue P, Zhu Y, et al. Discovery of novel azetidine amides as potent small-molecule STAT3 inhibitors. J Med Chem. 2021;64(1):695–710.
   PubMed Web of Science ®Google Scholar
• University of Hawaii. Aryl sulfonamides as small molecule STAT3 inhibitors. WO2021016333. 2021.
   Google Scholar
• Weidler M, Rether J, Anke T, et al. Inhibition of interleukin-6 signaling by galiellalactone. FEBS Lett. 2000;484(1):1–6.
   PubMed Web of Science ®Google Scholar
• Don-Doncow N, Escobar Z, Johansson M, et al. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. J Biol Chem. 2014;289(23):15969–15978.
   PubMed Web of Science ®Google Scholar
• Escobar Z, Bjartell A, Canesin G, et al. Preclinical characterization of 3β-(N-acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a prodrug of a direct STAT3 inhibitor for the treatment of prostate cancer. J Med Chem. 2016;59(10):4551–4562.
   PubMed Web of Science ®Google Scholar
• Johansson M, Sterner O. Tricyclic prodrugs. WO2015132396. 2015.
   Google Scholar
• Johansson M, Sterner O. Sulfonamide analogues of galiellalactone. WO2018104295. 2018.
   Google Scholar
• Chang LC, Turkson J, Wongwiwatthananukit S, et al. Novel sesquiterpenoid STAT3 inhibitors. WO2014205416. 2014.
   Google Scholar
• Miklossy G, Youn UJ, Yue P, et al. Hirsutinolide series inhibit Stat3 activity, alter GCN1, MAP1B, Hsp105, G6PD, vimentin, TrxR1, and importin α-2 expression, and induce antitumor effects against human glioma. J Med Chem. 2015;58(19):7734–7748.
   PubMed Web of Science ®Google Scholar
• Zhou GB, Cheng YX, Liu YQ. STAT3 inhibitor and application in pharmaceutical industry. CN104161750. 2014.
   Google Scholar
• Cheng X, Liu YQ, Wang GZ, et al. Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor. Oncotarget. 2017;8(2):2681–2693.
   PubMedGoogle Scholar
• Liu Y, Li S, Li J, et al. Application of compound separated and extracted from burdock to serving as STAT3 inhibitor. CN105640939. 2016
   Google Scholar
• Feng TT, Cao W, Shen WX, et al. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy. Oncotarget. 2017;8(1):329–344.
   PubMedGoogle Scholar
• Zhang T, Li JJ, Yin F, et al. Application of traditional Chinese medicine monomer toosendanin as STAT3 inhibitor in preparation of osteosarcoma resisting drug. CN107028957. 2017.
   Google Scholar
• Zhang T, Li J, Yin F, et al. Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. Oncogene. 2019 Jun;38(23):4655–4656. Oncogene. 2017;36(47):6627-39.
   PubMed Web of Science ®Google Scholar
• Guo C, Yang QJ, Chen LL. STAT3 inhibitor and application thereof. CN111205299. 2020.
   Google Scholar
• Chen LL, Xu WH, Yang QJ, et al. Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3. Pharmacol Res. 2020;158:104871.
   PubMed Web of Science ®Google Scholar
• Li YX, Gao DD, Zhang MM, et al. (S)-N-(1-phenethyl) thioacetamide compound as well as medicinal composition and application thereof. CN106957279. 2017.
   Google Scholar
• Gao DD, Jin N, Fu YX, et al. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors. Eur J Med Chem. 2021;216:113333.
   PubMed Web of Science ®Google Scholar
• Hartley JA, Kiakos K, Lee MN. 3,5-Diarylidenyl-N-substituted-piperid-4-one-derived inhibitors of STAT3 pathway acitivty and uses therof. WO2019097080. 2019.
   Google Scholar
• Ye FQ, He Q, Du XZ, et al. 4-methoxyl-N-(1-naphthyl) benzenesulfonamide STAT3 small molecular inhibitor, and preparation and applications thereof. CN110467551. 2019.
   Google Scholar
• Thurston DE, Khondaker MR, Mahar KS. Sulfonamide derivatives as STAT3 inhibitors for the treatment of proliferative diseases. WO2019030538. 2019.
   Google Scholar
• LaPorte MG, Wang Z, Colombo R, et al. Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. Bioorg Med Chem Lett. 2016;26(15):3581–3585.
   PubMed Web of Science ®Google Scholar
• Huryn DM, Wipf P, Grandis JR, et al. 6-Aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity. WO2016115455. 2016.
   Google Scholar
• Johnston PA, Sen M, Hua Y, et al. HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol. 2015;13(7):356–376.
   PubMed Web of Science ®Google Scholar
• Chen YH, Zhou WB, Chen H, et al. Class of triaromatic compounds targeting bifunctional phosphorylation site of STAT3 and applications thereof. WO2021017880. 2021.
   Google Scholar
• Huang RZ, Jing XT, Huang XC, et al. Bifunctional naphthoquinone aromatic amide-oxime derivatives exert combined immunotherapeutic and antitumor effects through simultaneous targeting of indoleamine-2,3-dioxygenase and signal transducer and activator of transcription 3. J Med Chem. 2020;63(4):1544–1563.
   PubMed Web of Science ®Google Scholar
• Wang HS, Jing XT, Huang RZ, et al. Oximino naphthoquinone compound and preparation and application methods thereof. CN109438277. 2019.
   Google Scholar
• Chang K, Jamroskovic J, Doimo M. Compounds targeting dual G-quadruplex DNA and STAT3. WO2020263164. 2020.
   Google Scholar
• Jamroskovic J, Doimo M, Chand K, et al. Quinazoline ligands induce cancer cell death through selective STAT3 inhibition and G-quadruplex stabilization. J Am Chem Soc. 2020;142(6):2876–2888.
   PubMed Web of Science ®Google Scholar
• Toure M, Crews CM. Small-molecule PROTACS: new approaches to protein degradation. Angew Chem Int Ed Engl. 2016;55(6):1966–1973.
   PubMed Web of Science ®Google Scholar
• Neklesa TK, Winkler JD, Crews CM. Targeted protein degradation by PROTACs. Pharmacol Ther. 2017;174:138–144.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang YJ, Xing DM, et al. PROTACs technology for targeting non-oncoproteins: advances and perspectives. Bioorg Chem. 2021;114:105109.
   PubMed Web of Science ®Google Scholar
• Bai LC, Zhou HB, Xu RQ, et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell. 2019;36(5):498–511.e17.
   PubMed Web of Science ®Google Scholar
• Zhou HB, Bai LC, Xu RQ, et al. Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein. J Med Chem. 2019;62(24):11280–11300.
   PubMed Web of Science ®Google Scholar
• Wang SM, Zhou HB, Xu RQ, et al. Small molecule degraders of STAT3. WO2020198435. 2020.
   Google Scholar
• Wang SM, Zhou HB, Xu RQ. STAT3 protein degraders. WO2020205467. 2020.
   Google Scholar
• Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001;276(48):45443–45455.
   PubMed Web of Science ®Google Scholar
• Tošić I, Frank DA. STAT3 as a mediator of oncogenic cellular metabolism: pathogenic and therapeutic implications. Neoplasia. 2021;23(12):1167–1178.
   PubMed Web of Science ®Google Scholar
• Bharadwaj U, Kasembeli MM, Robinson P, et al. Targeting janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution. Pharmacol Rev. 2020;72:486–526.
   PubMed Web of Science ®Google Scholar
• Santoni M, Miccini F, Cimadamore A, et al. An update on investigational therapies that target STAT3 for the treatment of cancer. Expert Opin Investig Drugs. 2021;30(3):245–251.
   PubMed Web of Science ®Google Scholar
• Huang WK, Lu SY, Huang ZM, et al. Allosite: a method for predicting allosteric sites. Bioinformatics. 2013;29(18):2357–2359.
   PubMed Web of Science ®Google Scholar
• Song K, Liu XY, Huang WK, et al. Improved method for the identification and validation of allosteric sites. J Chem Inf Model. 2017;57(9):2358–2363.
   PubMed Web of Science ®Google Scholar
• Clarke D, Sethi A, Li S, et al. Identifying allosteric hotspots with dynamics: application to inter- and intra-species conservation. Structure. 2016;24(5):826–837.
   PubMed Web of Science ®Google Scholar
• Xu YX, Wang SW, Hu QW, et al. CavityPlus: a web server for protein cavity detection with pharmacophore modelling, allosteric site identification and covalent ligand binding ability prediction. Nucleic Acids Res. 2018;46(W1):W374–W79.
   PubMed Web of Science ®Google Scholar
• Huang M, Song K, Liu XY, et al. AlloFinder: a strategy for allosteric modulator discovery and allosterome analyses. Nucleic Acids Res. 2018;46(W1):W451–W458.
   PubMed Web of Science ®Google Scholar
• Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update. [cited 2022 February 14]; Available from: https://www.biospace.com/article/releases/kymera-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-provides-a-business-update/
   Google Scholar